Enzyme replacement therapy with recombinant human ASB ( rhASB ) has been studied in a randomized , double-blind , two-dose ( 0.2 and 1.0 mg/kg/week ) phase I/II study ( n = 7 ) followed by an open-label single dose ( 1.0 mg/kg/week ) extension study .
